Not All p16-Positive Head and Neck Carcinomas are HPV-related: A Correlation Between p16 Immunohistochemistry and HPV Testing
This study demonstrates that p16 immunohistochemistry alone is an imperfect surrogate for high-risk HPV status in head and neck carcinomas due to its moderate specificity, highlighting the necessity of confirming HPV infection with molecular testing and integrating clinical and histopathologic context to avoid misdiagnosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the landscape of head and neck cancers, a specific type of tumor has emerged as a distinct entity with a notably better outlook than its counterparts. This is the squamous cell carcinoma of the oropharynx, the area at the back of the throat that includes the tonsils and the base of the tongue. For decades, doctors have known that many of these tumors are driven by the human papillomavirus, a common infection that, in this specific context, acts as the primary engine for the cancer's growth. Because these virus-driven tumors respond differently to treatment and often allow patients to survive longer, distinguishing them from non-viral cancers is critical. To make this distinction quickly and efficiently, pathologists rely on a biological marker called p16. Think of p16 as a flag that cells raise when they are being hijacked by the virus; when a microscope reveals a strong presence of this flag, it is usually taken as proof that the virus is the cause. This method has become the standard way to sort patients into different treatment paths.
However, the relationship between this flag and the virus is not as absolute as once believed. A recent study from Albany Medical Center investigated a group of fifty-four patients with head and neck tumors to see what happens when the p16 flag is raised, but the virus itself cannot be found. The researchers looked at tissue samples from patients who had undergone biopsies or surgeries between 2021 and 2025. They used two different tests on each sample: one to look for the p16 protein and another, more direct test, to search for the genetic material of high-risk HPV. By comparing the results, they aimed to understand how often the p16 test gives a false alarm and what kinds of tumors might be responsible for these confusing cases.
The study revealed that while the p16 test is excellent at catching most virus-driven cancers, it is not perfect at ruling out other causes. Out of the fifty-four cases examined, twenty-six showed a match: the p16 flag was up, and the virus was present. These were the clear-cut cases of HPV-driven cancer. Yet, in eighteen other cases, the p16 flag was up, but the virus test came back negative. This group included tumors from various locations, such as the soft palate, the nasal vestibule, and even the base of the tongue. Most notably, one of these p16-positive but virus-negative tumors was a polymorphous adenocarcinoma, a rare type of cancer that does not typically arise from HPV. Another was a squamous cell carcinoma of the soft palate. The researchers found that in these instances, the p16 protein was being produced for reasons other than the virus, likely due to other cellular errors that happen to trigger the same biological pathway.
The investigation also uncovered the reverse scenario, though it was much rarer. In two cases, the virus was clearly present, yet the p16 flag was missing or very faint. These were squamous cell carcinomas where the virus was driving the cancer, but the tumor had somehow lost the ability to produce the p16 protein. This suggests that relying solely on the p16 test can occasionally miss a virus-driven cancer or, conversely, mislabel a non-viral cancer as one. When the researchers calculated the performance of the p16 test across their entire group, they found it was highly sensitive, correctly identifying 92.9 percent of the virus-driven cancers. However, its specificity was only 84.6 percent, meaning that about one in six times it flagged a tumor as virus-driven, it was actually a false positive.
The core message from this work is that the p16 test is a powerful tool, but it is not a standalone verdict. The researchers emphasize that a positive p16 result must be weighed against the specific location of the tumor, its microscopic appearance, and the patient's clinical history. In the oropharynx, where HPV-driven cancers are most common, the test is very reliable. But in other parts of the head and neck, or when the tumor looks unusual under the microscope, a positive p16 result does not guarantee that the virus is the culprit. The study concludes that pathologists and doctors should not treat a p16-positive result as a definitive diagnosis of HPV-related disease without considering the broader context. When the visual clues of the tumor do not match the p16 result, or when the tumor is in a less common location, a direct test for the virus is necessary to ensure the patient receives the correct diagnosis and treatment plan.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.